Bisphosphonates: Mode of Action and Pharmacology

Pediatrics

Volumn 119, Issue SUPPL. 2, 2007, Pages

  Russell, R Graham G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Bisphosphonates; Bone resorption; Osteoclasts; Osteoporosis

Indexed keywords

ADENOSINE TRIPHOSPHATE; ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CLODRONIC ACID; ETIDRONIC ACID; FARNESYL DIPHOSPHATE; GERANYLTRANSFERASE; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IBANDRONIC ACID; INCADRONIC ACID; ISOPRENOID; MEVALONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; PLACEBO; RAB PROTEIN; RAC PROTEIN; REGULATOR PROTEIN; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RISEDRONIC ACID; TILUDRONIC ACID; ZOLEDRONIC ACID;

ALBERS SCHOENBERG DISEASE; BIOSYNTHESIS; BONE ATROPHY; BONE DISEASE; BONE METASTASIS; BONE NECROSIS; BONE STRENGTH; BONE STRUCTURE; CALCIUM METABOLISM; CELL ACTIVITY; CLINICAL TRIAL; CONFERENCE PAPER; CRYSTAL STRUCTURE; DRUG ACTIVITY; DRUG BINDING; DRUG MECHANISM; DRUG MEGADOSE; FRACTURE; FRACTURE HEALING; HUMAN; HYPERCALCEMIA; JAW DISEASE; MYELOMA; NONHUMAN; OSSIFYING MYOSITIS; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOPOROSIS; PAGET BONE DISEASE; PRENYLATION; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; SINGLE DRUG DOSE; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANIMALS; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; CALCIFICATION, PHYSIOLOGIC; CHILD; DIPHOSPHONATES; DRUG ADMINISTRATION ROUTES; DRUG ADMINISTRATION SCHEDULE; DRUG EVALUATION; HUMANS; OSTEOCLASTS; TREATMENT OUTCOME;

EID: 33947109369     PISSN: 00314005     EISSN: 02105721     Source Type: Journal    
DOI: 10.1542/peds.2006-2023H     Document Type: Conference Paper

References (155)

1. Russell RGG. Bisphosphonates: from bench to bedside. Ann N Y Acad Sci. 2006;1068:367-401
2. Bijvoet O, Fleisch H, Canfield RE, Russell RGG, eds. Bisphosphonates on Bone. Amsterdam, Holland: Elsevier Science; 1995
3. Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient. 4th ed. San Diego, CA: Academic Press; 2000
4. Green JR. Bisphosphonates: preclinical review. Oncologist. 2004;9(suppl 4):3-13
5. Rogers MJ. From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates. Calcif Tissue Int. 2004;75:451-461
6. Fleisch H, Neuman WF. Mechanisms of calcification: role of collagen, polyphosphates, and phosphatase. Am J Physiol. 1961;200:1296-1300
7. Fleisch H, Bisaz S. Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol. 1962;203:671-675
8. Fleisch H, Russell RGG, Straumann F. Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature. 1966;212:901-903
9. Russell RG. Excretion of inorganic pyrophosphate in hypophosphatasia. Lancet. 1965;10:461-464
10. 3 in rats. Clin Sci. 1968;35:363-372
11. Fleisch H, Russell RGG, Bisaz S, Casey PA, Muehlbauer RC. The influence of pyrophosphate analogues (diphosphonates) on the precipitation and dissolution. Calcif Tissue Res. 1968;(suppl):10-10A
12. Francis MD, Russell RGG, Fleisch H. Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science. 1969;165:1264-1266
13. Fleisch H, Russell RGG, Francis MD. Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture in vivo. Science. 1969;165:1262-1264
14. Jung A, Bisaz S, Fleisch H. The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res. 1973;11:269-280
15. Fleisch H, Russell RGG, Bisaz S, Muehlbauer RC, Williams DA. The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney recalcification in vivo. Eur J Clin Invest. 1970;1:12-18
16. Schenk R, Merz WA, Muhlbauer R, Russell RGG, Fleisch H. Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res. 1973;11:196-214
17. Fleisch H, Maerki J, Russell RGG. Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proc Soc Exp Biol Med. 1966;122:317-320
18. Russell RGG, Muhlbauer RC, Bisaz S, Williams DA, Fleisch H. The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats. Calcif Tissue Res. 1970;6:183-196
19. Trechsel U, Stutzer A, Fleisch H. Hypercalcemia induced with an arotinoid in thyroparathyroidectomized rats: a new model to study bone resorption in vivo. J Clin Invest. 1987;80:1679-1686
20. Stutzer A, Fleisch H, Trechsel U. Short- and long-term effects of a single dose of bisphosphonates on retinoid-induced bone resorption in thyroparathyroidectomized rats. Calcif Tissue Int. 1988;43:294-299
21. Schenk R, Eggli P, Fleisch H, Rosini S. Quantitative morphometric evaluation of the inhibitory activity of new aminobisphosphonates on bone resorption in the rat. Calcif Tissue Int. 1986;38:342-349
22. Muehlbauer RC, Russell RGG, Williams DA, Fleisch H. The effects of diphosphonates, polyphosphates, and calcitonin on "immobilisation osteoporosis" in rats. Eur J Clin Invest. 1971;1:336-344
23. Ferretti JL. Effects of biosphosphonates on bone biomechanics. Bijvoet O, Fleisch HA, Canfield RE, Russell RGG, eds. In: Bisphosphonates on Bone. Amsterdam, Holland: Elsevier Science; 1995:211-229
24. Shinoda H, Adamek G, Felix R, Fleisch H, Schenk R, Hagan P. Structure-activity relationships of various bisphosphonates. Calcif Tissue Int. 1983;35:87-99
25. Flanagan AM, Chambers TJ. Dicholormethylenebisphosphonate (C12MBP) inhibits bone resorption through injury to osteoclasts that resorb C12 MBP-coated bone. Bone Miner. 1989;6:33-43
26. Smith R, Russell RGG, Bishop M. Disphosphonates and Page's disease of bone. Lancet. 1971;1(7706):945-947
27. Reitsma PH, Bijvoet OLM, Verlinden-Ooms H, van der Wee-Pals LJA. Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxy-propylidene)-1,1-bisphosphonate (APD) in rats. Calcif Tissue Int. 1980;32:145-157
28. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 1994;79:1693-1700
29. Bauss F, Russell RG. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos Int. 2004;15:423-433
30. Gasser JA, Green JR. Long-term protective effect of a single IV injection of zoledronic acid on cancellous bone structure and cortical bone in ovariectomized rats. Bone. 2002;30(suppl):41S
31. Hughes DE, MacDonald BR, Russell RG, Gowen M. Inhibition of osteoclast-like cell formation by bisphosphonates in longterm cultures of human bone marrow. J Clin Invest. 1989;83:1930-1935
32. Boonekamp PM, van der Wee-Pals LJA, van Wijk-van Lennep MLL, Wil Thesing C, Bijvoet OLM. Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner. 1986;1:27-39
33. Lowik CWGM, van der Pluijm G, van der Wee-Pals LJA, Bloys van Teslong-de Groot H, Bijvoet OLM. Migration and phenotypic transformation of osteoclast precursors into mature osteoclasts: the effect of a bisphosphonate. J Bone Miner Res. 1988;3:185-192
34. Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res. 1997;12:869-879
35. 3H-etidronate in rat and mouse bones. Bone. 1996;19:281-290
36. Azuma Y, Sato H, Oue Y, et al. Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone. 1995;16:235-245
37. Sato M, Grasser W. Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res. 1990;5:31-40
38. Plotkin LI, Weinstein RS, Parfitt AM, Roberson PK, Manolagas Sc, Bellido T. Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest. 1999;104:1363-1374
39. Plotkin LI, Aguirre JI, Kousteni S, Manolagas SC, Bellido T. Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation. J Biol Chem. 2005;280:7317-7325
40. Ebrahimpour A, Francis MD. Bisphosphonate therapy in acute and chronic bone loss: physical chemical considerations in bisphosphonate-related therapies. In: Bijvoet O, Fleisch HA, Canfield RE, Russell RGG eds. Bisphosphonates on Bones. Amsterdam, Holland: Elsevier Science; 1995:125-136
41. Muehlbauer RC, Bauss F, Schenk R, et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J Bone Miner Res. 1991;6:1003-1011
42. Papapoulos SE, Hoekman K, Lowik CWGM, Vermeij P, Bijvoet OLM. Application of an in vitro model and a clinical protocol in the assessment of the potency of a new bisphosphonate. J Bone Miner Res. 1988;4:775-781
43. Goa KL, Balfour JA. Risedronate. Drugs Aging. 1998;13:83-91; discussion 92
44. Green JR, Mueller K, Jaeggi KA. Preclinical pharmacology of CGP42'446, a new, potent, heterocyclic bisphosphonate compound. J Bone Miner Res. 1994;9:745-751
45. Ebetino FH, Bayless AV, Amburgey J, Ibbotson KJ, Dansereau S, Ebrahimpour A. Elucidation of a pharmacore for the bisphosphonate mechanism of bone antiresorptive activity. Phosphorus Sulfur Silicon Relat Elem. 1996;109/110:217-220
46. van Beek E, Lowik C, Oue I, Papapoulos S. Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group. J Bone Miner Res. 1996;11:1492-1497
47. David P, Nguyen H, Barbier A, Baron R. The bisphosphonate tiludronate is a potent inhibitor of the osteoclast vacuolar H(+)-ATPase. J Bone Miner Res. 1996;11:1498-1507
48. Carano A, Teitelbaum SA, Konsek JD, Schlesinger PH, Blair HC. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest. 1990;85:456-461
49. Felix R, Russell RGG, Fleisch H. The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta. 1976;429:429-438
50. Lerner UH, Larsson A. Effects of four bisphosphonates on bone resorption, lysosomal enzyme release, protein synthesis, and mitotic activities in mouse calvarial bones in vitro. Bone. 1987;8:179-189
51. Sato M, Grasser W, Endo N, et al. Bisphosphonate action: alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest. 1991;88:2095-2105
52. Murakami H, Takahashi N, Sasaki T, et al. A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders. Bone. 1995;17:137-144
53. Schmidt A, Rutledge SJ, Endo N, et al. Alendronate inhibition of protein tyrosine phosphatase activity. Proc Natl Acad Sci U S A. 1995;93:3068-3073
54. Endo N, Rutledge SJ, Opas EE, Vogel R, Rodan GA, Schmidt A. Human protein tyrosine phosphatases: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res. 1996;11:535-543
55. Opas EE, Rutledge SJ, Golub E, et al. Alendronate inhibition of protein-tyrosine-phosphatase-meg1. Biochem Pharmacol. 1997;54:721-727
56. Murakami H, Takahashi N, Tanaka S, et al. Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts. Bone. 1997;20:399-404
57. Rogers MJ, Watts DJ, Russell RGG, et al. Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. J Bone Miner Res. 1994;9:1029-1039
58. Rogers MJ, Xiong X, Brown RJ, et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol. 1995;47:398-402
59. Rogers MJ, Brown RJ, Hodkin V, Russell RGG, Watts DJ. Bisphosphonates are incorporated into adenine nucleotides by human aminoacyl-tRNA synthetase enzymes. Biochem Biophys Res Commun. 1996;224:863-869
60. Rogers MJ, Ji X, Russell RGG, et al. Incorporation of bisphosphonates into adenine nucleotides by amoebae of the cellular slime mould Dictyostelium discoideum. Biochem J. 1994;303:303-311
61. Frith JC, Monkkonen J, Blackburn GM, Russell RGG, Rogers MJ. Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5′β, γ-dichloromethylene triphosphate, by mammalian cells in vitro. J Bone Miner Res. 1996;12:1358-1367
62. Frith JC, Monkkonen J, Auriola S, Monkkonen H, Rogers MJ. The molecular mechanism of action of the antiresorptive and anti-inflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis. Arthritis Rheum. 2001;44:2201-2210
63. Rogers MJ, Xiong X, Ji X, et al. Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonates is dependent on cellular uptake. Pharm Res. 1997;14:625-630
64. Lehenkari PP, Kellinsalmi M, Napankangas JJJP, et al. Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable adenine-containing metabolite. Mol Pharmacol. 2002;61:1255-1262
65. Zhang FL, Casey PJ. Protein prenylation: molecular mechanisms and functional consequences. Annu Rev Biochem. 1996;65:241-269
66. Ridley AJ, Hall A. The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors. Cell. 1992;70:389-399
67. Ridley AJ, Paterson HF, Johnston CL, Diekmann D, Hall A. The small GTP-binding protein, rac, regulates growth factor-induced membrane ruffling. Cell. 1992;70:401-410
68. Zerial M, Stenmark H. Rab GTPases in vesicular transport. Curr Opin Cell Biol. 1993;5:613-620
69. Zhang D, Udagawa N, Nakamura I, et al. The small GTP-biding protein, Rho p21, is involved in bone resorption by regulating cytoskeletal organization in osteoclasts. J Cell Sci. 1995;108:2285-2292
70. Marshall C. Protein prenylation: a mediator of protein-protein interactions. Science. 1993;259:1865-1866
71. Luckman SP, Hughes DE, Coxon FP, Russell RGG, Rogers MJ. Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res. 1998;13:581-589
72. Luckman SP, Coxon FP, Ebetino FH, Russell RGG, Rogers MJ. Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages. J Bone Miner Res. 1998;13:1668-1678
73. Staal A, Frith JC, French MH, et al. The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity. J Bone Miner Res. 2003;18:88-96
74. Fisher JE, Rogers MJ, Halasy JM, et al. Mechanism of action of alendronate: geranylgeraniol, an intermediate of the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A. 1999;96:133-138
75. Hall A. Rho GTPases and the actin cytoskeleton. Science. 1998;279:509-514
76. Amin D, Cornell SA, Perrone MH, Bilder GE. 1-hydroxy-3- (methylpentylamino)-propylidene-1,1-bisphosphonic acid as a potent inhibitor of squalene synthase. Drug Res. 1996;46:759-762
77. Amin D, Cornell SA, Gustafson SK, et al. Bisphosphonates used for the treatment of bone disorders inhibit squalene synthase and cholesterol biosynthesis. J Lipid Res. 1992;33:1657-1663
78. van Beek E, Pieterman E, Cohen L, Lowik C, Papapoulos S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun. 1999;255:491-494
79. Dunford JE, Thompson K, Coxon FP, et al. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther. 2001;296:235-242
80. Ebetino FH, Roze CN, McKenna CE, et al. Molecular interactions of nitrogen-containing bisphosphonates within farnesyl diphosphate synthase. J Organometallic Chem. 2005;690:2679-2687
81. Kavanagh K, Guo K, Dunford J, et al. Human farnesyl diphosphate synthase (FDPS): crystal structure and molecular interactions with nitrogen-containing bisphosphonates. Proc Natl Acad Sci U S A. 2006;103:7829-7834
82. Martin MB, Arnold W, Heath HT 3rd, Urbina JA, Oldfield E. Nitrogen-containing bisphosphonates as carbocation transition state analogs for isoprenoid biosynthesis. Biochem Biophys Res Commun. 1999;263:754-758
83. Smith R. Ectopic calcification and ossification. In: Bijovoet O, Fleisch HA, Canfield RE, Russell RGG, eds. Bisphosphonates on Bone. Amsterdam, Holland: Elsevier Science; 1995:433-443
84. Fogelman I, Bessent RG, Turner JF, Citrin DL, Boyce IT, Greig WR. The use of whole-body retention of Tc-99m diphosphonate in the diagnosis of metabolic bone disease. J Nucl Med. 1978;19:270-275
85. Francis MD, Fogelman I. 99mTc-diphosphonate uptake mechanisms on bone. In: Fogleman I, ed. Bone Scanning in Clinical Practice. London, United Kingdom: Springer; 1987:1-6
86. Adami S, Zamberlan N. Adverse effects of bisphosphonates: a comparative review. Drug Saf. 1996;14:158-170
87. van Staa TP. Post-marketing survey with ICT-etidronate therapy. Rev Contemp Pharmacol. 1998;9:277-286
88. DeGroen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med. 1996;335:1016-1021
89. Russell RGG, Smith R, Preston C, Walton RJ, Woods CF. Diphosphonates in Paget's disease. Lancet. 1974;1(7863):894-898
90. Delmas PD, Meunier PJ. The management of Paget's disease of bone. N Engl J Med. 1997;336:558-566
91. Douglas DL, Russell RGG, Preston CJ, et al. Effect of dicholormethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease. Lancet. 1980;1(8177):1043-1047
92. Coukell AJ, Markham A. Pamidronate: a review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone. Drugs Aging. 1998;12:149-168
93. Singer FR, Clemens TL, Eusebio RE, Bekker PJ. Risedronate, a highly effective oral agent in the treatment of patients with severe Paget's disease. J Clin Endocrinol Metab. 1998;83:1906-1910
94. Siris ES, Chines AA, Altman RD, et al. Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study. J Bone Miner Res. 1998;13:1032-1038
95. Reid IR, Miller P, Lyles K, et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease. N Engl J Med. 2005;353:898-908
96. Ross JR, Saunders Y, Edmonds PM, et al. A systematic review of the role of bisphosphonates in metastatic disease. Health Technol Assess. 2004;8(4):1-176
97. Paterson AD, Kanis JA, Cameron EC, et al. The use of dichloromethylene diphosphonate for the management of hypercalcaemia in multiple myeloma. Br J Haematol. 1983;54:121-132
98. Ralston SH, Gallacher SJ, Patel U, Fraser WD, Dryburgh FJ, Boyle IT. Comparison of three bisphosphonates in cancer-associated hypercalcaemia. Lancet. 1989;2(8673):1180-1182
99. Body JJ. Hypercalcemia of malignancy. Semin Nephrol. 2004;24:48-54
100. Sirohi B, Powles R. Multiple myeloma. Lancet. 2004;363:875-887
101. Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005;(3):CD003474
102. Coleman RE. Bisphosphonates in breast cancer. Ann Oncol. 2005;16:687-695
103. Parker CC. The role of bisphosphonates in the treatment of prostate cancer. BJU Int. 2005;95:935-938
104. Smith MR. Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence. Cancer Treat Rev. 2005;31(suppl 3):19-25
105. Bell R. Efficacy of ibandronate in metastatic bone disease: review of clinical data. Oncologist. 2005;10(suppl 1):8-134
106. Body JJ, Diel IJ, Lichinitzer M, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies. Br J Cancer. 2004;90:1133-1137
107. McCloskey EV, MacLennan ICM, Drayson M, Chapman C, Dunn J, Kanis JA. A randomized trial of the effect of clodronate on skeletal morbidity in multiple myeloma. MRC Working Party on Leukeaemia in Adults. Br J Haematol. 1998;100:317-325
108. Berenson JR, Lichtenstein A, Porter L, et al. Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:488-493
109. Diel IJ, Solomayer EF, Costa SD, et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357-363
110. Maerevoet M, Martin C, Duck L. Osteonecrosis of the jaw and bisphosphonates [published correction appears in N Engl J Med. 2005;353:2728]. N Engl J Med. 2005;353:99-102
111. Carmona RH. Bone Health and Osteoporosis: A Report of the Surgeon General. Rockville MD: US Department of Health and Human Services, Office of the Surgeon General; 2004. Available at: www.hhs.gov/surgeongeneral/library/ bonehealth/content.html. Acessed December 13, 2006
112. Russell RGG. Pathogenesis of osteoporosis. In: Hochberg MC, Silman AJ, Smolen SJ, Weinblatt ME, Weisman MH, eds. Rheumatology. 3rd ed. St Louis, MO: Mosby; 2003:2075-2147
113. Watts NB, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73-79
114. Storm T, Thamsborg G, Steinriche T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med. 1990;322:1265-1271
115. van Staa TP, Abenhain L, Cooper C. Use of cyclical etidronate and prevention of non-vertebral fractures. Br J Rheumatol. 1998;37:87-94
116. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-1443
117. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996;348:1535-1541
118. Bone HG, Hosking D, Devogelaer JP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004;350:1189-1199
119. Reginster J, Minne HW, Sorenson OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11:83-91
120. McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344:333-340
121. Boonen S, Laan RF, Barton IP, Watts NB. Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies. Osteoporos Int. 2005;16:1291-1298
122. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997;100:1475-1480
123. Adachi JD, Bensen WG, Brown J, et al. Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis. N Engl J Med. 1997;337:381-387
124. Saag KG, Emkey K, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group. N Engl J Med. 1998;339:292-299
125. Chesnut CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004;19:1241-1249
126. Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med. 2002;346:653-661
127. Glorieux FH, Bishop NJ, Plotkin H, Chabot G, Lanoue G, Travers R. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947-952
128. Rauch F, Glorieux FH. Osteogenesis imperfecta, current and future medical treatment. Am J Med Genet C Semin Med Genet. 2005;139:31-37
129. Borah B, Ritman EL, Dufresne TE, et al. The effect of risedronate on bone mineralization as measured by microcomputed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover. Bone. 2005;37:1-9
130. Borah B, Dufresne TE, Chmielewski PA, Gross GJ, Prenger MC, Phipps RJ. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J Bone Miner Res. 2002;17:1139-1147
131. Borah B, Dufresne TE, Chmielweski PA, Johnson TD, Chines A, Manhart MD. Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography. Bone. 2004;34:736-746
132. Lalla S, Hothorn LA, Haag N, Bader R, Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos Int. 1998;8:97-103
133. Bauss F, Lalla S, Endele R, Hothorn LA. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J Rheumatol. 2002;29:2200-2208
134. MashibaT, Mori S, Burr DB, et al. The effects of suppressed bone remodeling by bisphosphonates on microdamage accumulation and degree of mineralization in the cortical bone of dog rib. J Bone Miner Metab. 2005;23(suppl):36-42
135. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB. Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2000;15:613-620
136. Flora L, Hassing GS, Cloyd GG, Bevan JA, Parfitt AM, Villanueva AR. The long-term skeletal effects of EHDP in dogs. Metab Bone Dis Relat Res. 1981;3:389-300
137. Odvina CV, Zerwekh JE, Rao DS, Malouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2005;90:1294-1301
138. Ott SM. Long-term safety of bisphosphonates. J Clin Endocrinol Metab. 2005;90:1897-1899
139. Whyte MP, Wenkert D, Clements KL, McAlister WH, Mumm S. Bisphosphonate-induced osteopetrosis. N Engl J Med. 2004;349:457-463
140. Monier-Faugere MC, Geng Z, Paschalis EP, et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J Bone Miner Res. 1999;14:1768-1778
141. Bauss F, Schenk RK, Hort S, Muller-Beckmann B, Sponer G. New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a longterm study with ibandronate. J Pharmacol Toxicol Methods. 2004;50:25-34
142. Little DG, McDonald M, Bransford R, Godfrey CB, Amanat N. Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model. J Bone Miner Res. 2005;20:2044-2052
143. Kurth AH, Eberhardt C, Muller S, Steinacker M, Schwarz M, Bauss F. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone. 2005;37:204-210
144. Wilkinson JM, Eagleton AC, Stockley I, Peel NF, Hamer AJ, Eastell R. Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial. J Orthop Res. 2005;23:1-8
145. Little DG, Smith NC, Williams PR, et al. Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis. J Bone Miner Res. 2003;18:1300-1307
146. Little DG, Peat RA, Mcevoy A, Williams PR, Smith EJ, Baldock PA. Zoledronic acid treatment results in retention of femoral head structure after traumatic osteonecrosis in young Wistar rats. J Bone Miner Res. 2003;18:2016-2022
147. Lai KA, Shen WJ, Yang CY, Shao CJ, Hsu JT, Lin RM. The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis: a randomized clinical study. J Bone Joint Surg Am. 2005;87:2155-2159
148. Little DG, McDonald M, Sharpe IT, Peat R, Williams P, McEvoy T. Zoledronic acid improves femoral head sphericity in a rat model of Perthes disease. J Orthop Res. 2005;23:862-868
149. Nancollas GH, Tang R, Phipps RJ, et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone. 2006;38:617-627
150. Sauty A, Pecherstorfer M, Zimmeroth I, et al. Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy. Bone. 1996;18:133-139
151. Schweitzer DH, Oostendorp-vande Ruit M, van der Pluijm G, Lowik CWGM, Papapoulos SE. Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroyxpoproylidene bisphosphonate. J Bone Miner Res. 1995;10:956-962
152. Sanders JM, Ghosh S, Chan JM, et al. Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates. J Med Chem. 2004;47:375-384
153. Thompson K, Rogers MJ. Statins prevent bisphosphonateinduced gamma, delta T-cell proliferation and activation in vitro. J Bone Miner Res. 2004;19:278-288
154. Gabelli SB, McLellan JS, Montalvetti A, Oldfield E, Docampo R, Amzel LM. Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design. Proteins. 2005;62:80-88
155. Szabo CM, Matsumura Y, Fukura S, et al. Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents. J Med Chem. 2002;45:2185-2196